Emanuele Montomoli (CSO & Founder) and Alessandro Manenti (CDO) are co-authors of a new scientific publication on a Phase II/III clinical study evaluating the immunogenicity, safety, and tolerability of a new SARS-CoV-2 booster vaccine.
The study represents an important international collaboration between VisMederi and several Argentinian partners, including the Instituto de Investigaciones Biotecnológicas and the Universidad Nacional de San Martín.
📄 The full article is available here:
🔗 Read on ScienceDirect
